Mesenchymal Stem Cells: Time to Change the Name!
Mesenchymal Stem Cells: Time to Change the Name!
复制标题
DOI：
10.1002/sctm.17-0051
复制
发表时间：
2017-06
影响因子：
6
通讯作者：
Caplan AI
中科院分区：
文献类型：
--
作者：
Caplan AI
间充质干细胞 (MSC) 于 25 年前被正式命名，代表一类来自人类和哺乳动物骨髓和骨膜的细胞，可以在培养物中分离和扩增，同时保持其体外诱导形成各种中胚层表型和组织的能力。体外形成骨骼、软骨、脂肪等的能力成为鉴定此类多能细胞的一种检测方法，并围绕该检测方法在 20 世纪 90 年代成立了几家公司，以在医学上利用 MSC 的再生能力。如今，有数百家诊所和数百项临床试验使用人类间充质干细胞，但很少（如果有的话）关注这些细胞的体外多潜能能力。不幸的是，间充质干细胞被称为“干细胞”这一事实被用来推断患者将获得直接的医疗益处，因为他们认为这些细胞将分化为再生组织生成细胞。这种干细胞治疗可能会治愈患者的医学相关困难，从骨关节炎（骨对骨）膝盖到包括痴呆在内的各种神经系统疾病。我现在敦促我们将间充质干细胞的名称更改为“医学信号细胞”，以更准确地反映这些细胞定位于损伤或疾病部位并分泌免疫调节和营养（再生）生物活性因子的事实，这意味着这些细胞可以在原位制造药用治疗药物。事实上，患者自身的位点特异性和组织特异性驻留干细胞在外源性 MSC 分泌的生物活性因子的刺激下构建了新组织。干细胞转化医学 2017；6：1445–1451
Mesenchymal stem cells (MSCs) were officially named more than 25 years ago to represent a class of cells from human and mammalian bone marrow and periosteum that could be isolated and expanded in culture while maintaining their in vitro capacity to be induced to form a variety of mesodermal phenotypes and tissues. The in vitro capacity to form bone, cartilage, fat, etc., became an assay for identifying this class of multipotent cells and around which several companies were formed in the 1990s to medically exploit the regenerative capabilities of MSCs. Today, there are hundreds of clinics and hundreds of clinical trials using human MSCs with very few, if any, focusing on the in vitro multipotential capacities of these cells. Unfortunately, the fact that MSCs are called “stem cells” is being used to infer that patients will receive direct medical benefit, because they imagine that these cells will differentiate into regenerating tissue‐producing cells. Such a stem cell treatment will presumably cure the patient of their medically relevant difficulties ranging from osteoarthritic (bone‐on‐bone) knees to various neurological maladies including dementia. I now urge that we change the name of MSCs to Medicinal Signaling Cells to more accurately reflect the fact that these cells home in on sites of injury or disease and secrete bioactive factors that are immunomodulatory and trophic (regenerative) meaning that these cells make therapeutic drugs in situ that are medicinal. It is, indeed, the patient's own site‐specific and tissue‐specific resident stem cells that construct the new tissue as stimulated by the bioactive factors secreted by the exogenously supplied MSCs. Stem Cells Translational Medicine 2017;6:1445–1451
登录
查看更多内容
影响因子：
23.9
作者：
Caplan AI;Correa D
通讯作者：
Correa D
DOI：
10.1073/pnas.72.5.1852
发表时间：
1975-01-01
影响因子：
11.1
作者：
CAPLAN, AI;ROSENBERG, MJ
通讯作者：
ROSENBERG, MJ
DOI：
10.1073/pnas.70.6.1713
发表时间：
1973-01-01
影响因子：
11.1
作者：
CAPLAN, AI;STOOLMILLER, AC
通讯作者：
STOOLMILLER, AC
影响因子：
56.9
作者：
CAPLAN, AI;ZWILLING, E;KAPLAN, NO
通讯作者：
KAPLAN, NO
影响因子：
4
作者：
Caplan, Arnold I.;Dennis, James E.
通讯作者：
Dennis, James E.